Report from the European Society of Cardiology Congress 2022 in Barcelona: new discoveries in cardiovascular pharmacotherapy

Abstract

The following paper presents an overview of the key studies presented at the European Society of Cardiology Congress 2022. The DELIVER study provided information on the efficacy of dapagliflozin independent of left ventricular ejection fraction. The ADVOR trial confirmed the beneficial effect of the inclusion of acetazolamide as a diuretic in the initial phase of acute decompensated heart failure. The REVIVED study showed no advantage of percutaneous revascularisation over optimal pharmacotherapy in stable coronary artery disease. The SECURE study demonstrated the benefit of the so-called polypill over taking each drug separately. The PANTHER meta-analysis indicated a better effect of using P2Y12 inhibitors over aspirin in chronic therapy. The ALL-HEART study revealed no benefit in treating asymptomatic hyperuricemia in patients with coronary artery disease with allopurinol. The INVICTUS trial demonstrated the superiority of vitamin K antagonists over non-vitamin K antagonist oral anticoagulants in preventing embolic complications in cases where valvular defects of rheumatic origin co-occur with atrial fibrillation.